Long-term stimuli of many systems leads to decreased cellular responsiveness, or desensitization. We characterized the desensitization of angiotensin II (Ang 11)-mediated inositol phospholipid (IP) hydrolysis in cultured human aortic smooth muscle cells (HASMC). Although it has been suggested that the desensitization induced by long-term Mg II exposure may result partially from down-regulation of Ang II receptor, this is not sufficient to explain fully desensitization in many systems. Post-receptor desensitization of IP hydrolysis may also result from phosphorylation or changes in protein levels of the effector enzyme, PLC-β. We identified the major PLC-β isoenzymes expressed by HASMC as PLC-β1 and PLC-β3. Ang II pretreatment reduced IP accumulation induced by Ang II (1μM) in a time-dependent manner. Phorbol ester-12-myristrate-13-acetate (PMA), a protein kinase C (PKC) activator, also reduced Ang II-stimulated IP accumulation. These results suggest that PKC activation may negatively regulate Ang II-stimulated IP signaling in HASMC, similar to rat cells. In addition, PKC also reduced IP accumulation stimulated by A1F₄⁻, directly activating the G protein. It suggests that the majority of PKC-induced desensitization of Ang II-stimulated IP signaling occurs downstream of the Ang II receptor in HASMC. However, both PLC-β1 and PLC-β3, expected candidates for PKC phosphorylation, were phosphorylated independently of PKC activation or inhibition, indicating that PKC might not be involved in direct phosphorylation of PLC-β1 and PLC-β3. Furthermore, PLC-β1, but not PLC-β3, was highly phosphorylated under basal conditions, suggesting that PLC-β1 and PLC-β3 may play different roles in IP signaling in HASMC. / Graduation date: 2003

The morbidity of and the mortality from cardiac disease are higher in diabetic patients. Clinical and experimental evidence suggests that diabetes-induced changes at the level of myocardium can, at least partially, contribute to these cardiac problems. The mechanism(s) involved in this diabetic cardiomyopathy is still unclear, but one defect appears to occur in the alpha₁-adrenoceptor system. Altered myocardial sensitivity and responsiveness to alpha₁-adrenoceptor agonists have been reported in experimental diabetes mellitus. Stimulation of alpha₁-adrenoceptors is known to produce a positive inotropic effect and has been recently shown to stimulate the hydrolysis of phosphoinositides. To evaluate the possibility that the changes in the inotropic responsiveness to alpha₁-adrenoceptor stimulation in the diabetic heart could be linked to altered alpha₁-adrenoceptor-stimulated phosphoinositide turnover and further to the development of diabetic cardiomyopathy, we studied contractility and receptor-stimulated phosphoinositide turnover following norepinephrine (in the presence of propranolol) stimulation in right ventricles from male Wistar rats (200-225 g) which were made diabetic with streptozotocin (55 mg/kg, i.v.). Rats were sacrificed six weeks after the induction of diabetes. Diabetic rats were characterized by decreased body weight gain, hypoinsulinemia, hyperglycemia and hyperlipidemia. Stimulation of alpha₁-adrenoceptors by norepinephrine (in the presence of propranolol) in right ventricles resulted in the formation of inositol monophosphate (measured with a radioisotope method) and inositol 1,4,5-trisphosphate (measured with an inositol 1,4,5-trisphosphate protein binding assay kit) in a time- and concentration-dependent manner in both control and diabetic rats. The increase in inositol 1,4,5-trisphosphate levels preceded the increase in the alpha₁-adrenoceptor-mediated positive inotropic effect. Diabetic hearts showed a greater maximum inotropic response to norepinephrine stimulation and also had a higher inositol 1,4,5-trisphosphate levels. However, with the radioisotope method, a decreased inositol monophosphate formation was shown in diabetic hearts compared with controls. Omega-3 fatty acids supplementation (Promega[symbol omitted], 0.5 ml/kg/day) had no significant effect on the changes in norepinephrine-stimulated inositol monophosphate formation in diabetic hearts. In the presence of the cyclooxygenase inhibitor indomethacin or the thromboxane synthetase inhibitor imidazole, the norepinephrine-stimulated positive inotropic effect and inositol 1,4,5-trisphosphate formation were significantly increased in control hearts, but were unaltered in the hearts from diabetics. The addition of the prostacyclin synthetase inhibitor tranylcypromine reduced the norepinephrine-stimulated positive inotropic effect and inositol 1,4,5-trisphosphate formation only in diabetic hearts and had no effect in the controls. While inositol 1,4,5-trisphosphate may be able to mediate only transient inotropic effects produced by alpha₁-adrenoceptor stimulation, diacylglycerol may provoke a sustained positive inotropic effect by activating slow Ca²⁺ channels through stimulation of protein kinase C. Our results showed that the diabetic hearts had a higher protein kinase C activity in the membrane fraction compared with controls and this was accompanied by a decrease in cytosolic protein kinase C activity. The present study suggests that the increases in inositol 1,4,5-trisphosphate levels and the membrane fraction protein kinase C activity may be implicated in the increased inotropic responsiveness to alpha₁-adrenoceptor stimulation in the hearts of the streptozotocin-diabetic rats. The increases in inositol 1,4,5-trisphosphate level and protein kinase C activity could induce Ca²⁺ overload in the diabetic heart which might be involved in the development of diabetic cardiomyopathy. The results from the omega-3 fatty acid study indicate that the changes in cardiac alpha₁-adrenoceptor-mediated inositol phosphates formation cannot contribute to the previously described improved cardiac function of omega-3 fatty acid-treated streptozotocin-diabetic rats. The nature and physiological significance of the enhanced positive inotropic effect and inositol 1,4,5-trisphosphate formation in the control heart with the addition of indomethacin and imidazole is still unclear. The effect of tranylcypromine may indicate the participation of prostaglandins in mediating the enhanced alpha₁-inotropic effect of norepinephrine in the diabetic heart. / Pharmaceutical Sciences, Faculty of / Graduate

Le métabolisme des phosphoinositides est constitué d’un réseau complexe d’enzymes et de seconds messagers phospholipidiques et solubles cruciaux pour de nombreux processus cellulaires. Le phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), second messager très important dans la cellule est contrôlé par plusieurs phosphatases. La phosphatase PTEN, fréquemment mutée dans de nombreux cancers humains (glioblastome, cancer de la prostate, cancer du sein, …), le déphosphoryle en position 3 pour donner du phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Les cellules de mammifères possèdent également une activité « inositol 5-phosphatase » pour de nombreux dérivés du myo-inositol. C’est la protéine SHIP2 (SH2-containing Inositol 5-phosphatase 2), une lipide phosphatase membre de la famille des phosphatidylinositol polyphosphate 5-phosphatases qui est, entre autres, responsable de cette activité. <p>Le but de ce travail de thèse a été de mettre en évidence un rôle potentiel de SHIP2 et/ou PTEN dans un modèle murin de tumeurs stromales gastro-intestinales (GIST) ;ce modèle exprime une forme constitutivement active du récepteur tyrosine kinase Kit muté sur l’acide aminé 641. Les souris qui ont été générées par le groupe du Dr Brian Rubin (Lerner Research Institute and Taussig Cancer Center, Cleveland) sont dénommées, les souris KitK641E.<p>La caractérisation des souris KitK641E nous a permis de montrer que SHIP2 et PTEN étaient exprimés dans les cellules Kit positives, les cellules de Cajal et qu’ils semblaient régulés de façons différentes.<p>En effet, nous avons pu mettre en évidence une augmentation de l’expression de PTEN dans l’antre gastrique des souris KitK641E homozygotes. Cette augmentation d’expression a également été observée dans l’antre gastrique de souris double transgéniques KitK641E x PTEN+/- alors que l’expression de PTEN dans le foie, un tissu n’exprimant pas de cellules Kit positives, était bien diminuée. Des expériences de PCR quantitative ont également permis de montrer que cette augmentation d’expression de PTEN ne provenait pas d’une augmentation du taux d’ARNm mais qu’elle se situait plutôt au niveau post-traductionnel. Ces données nous permettent de conclure que l’augmentation d’expression de PTEN dans les cellules Kit positives des souris KitK641E homozygotes est influencée par l’activation constitutive du récepteur Kit. <p>A l’inverse, l’expression de SHIP2 dans les cellules Kit positives n’a pu être mise en évidence qu’après activation constitutive du récepteur Kit. En parallèle, l’étude des voies de signalisation dépendantes du récepteur Kit nous ont permis de montrer que la phosphorylation de PKB ne semblait pas être affectée et que ce serait plutôt la voie des MAPK kinases qui interviendrait dans ce modèle. <p>Nous avons également observé la localisation subcellulaire de SHIP2 et de PTEN en utilisant un modèle cellulaire de cellules GIST882 (cellules dérivées d’un GIST humain portant la mutation correspondante à notre modèle murin). Dans ce modèle, PTEN est principalement localisé dans le noyau alors que SHIP2 est localisé à la fois au sein du noyau et du cytoplasme. Ce modèle nous a également permis de montrer que la forme phosphorylée sur tyrosine de SHIP2 (Y1135) était localisée dans le noyau et qu’elle était modulée en fonction du cycle cellulaire.<p>En conclusion, ces travaux ont permis de montrer que dans le modèle de souris KitK641E, SHIP2 et PTEN étaient localisés au sein des cellules Kit positives et qu’ils étaient modulés par des mécanismes différents. L’augmentation d’expression de PTEN observée dans les souris KitK641E homozygotes pourrait constituer un mécanisme de rétrocontrôle négatif afin de modifier l’impact de voies de signalisation en aval du récepteur Kit dans ce modèle oncogénique.<p> / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished